Janssen-cilag Ltd.

This study follows 200 adults with psoriatic arthritis to see how many continue taking guselkumab for one year. Researchers will track treatment stops, switches, and reasons. The goal is to understand real-world use, not to test a cure.

This study watches 200 adults with moderate to severe psoriasis who switch from ustekinumab to guselkumab in everyday medical practice. Researchers track how well the new drug clears skin and check for side effects over 52 weeks. The goal is to see if switching helps patients ach…

This study is tracking 220 adults in the UK with moderate to severe ulcerative colitis or Crohn's disease who are starting guselkumab, a biologic treatment. Researchers want to see how well the drug controls symptoms and helps patients achieve remission without needing steroids. …

This study collects information from medical records of 900 people with relapsed/refractory multiple myeloma who received teclistamab or talquetamab outside of clinical trials. The goal is to understand how well these treatments work and how they are managed in everyday practice.…